A new PET/CT imaging technique that visualizes activated fibroblasts in the heart muscle enables early detection of multiple ...

GEHC's Flyrcado gains momentum with FDA approval, CMS support, and expanding coverage in cardiac PET imaging.

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is ...

Long COVID patients with abnormal cardiopulmonary PET/MR findings may be more likely to develop heart and lung diseases ...

GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission ...

PET-CT scans combine structural and functional imaging to detect diseases early. This technology improves diagnosis accuracy ...

QST team Members of the Imaging Physics Group with the total-body small-animal PET scanner. (Courtesy: Han Gyu Kang) Dynamic PET imaging is an important preclinical research tool used to visualize ...

PET/CT scans using ⁶⁸Ga-FAPI detected activated fibroblasts in 64 percent of patients, with half showing patchy and half showing extensive heart uptake.

Cardiac amyloidosis (CA) is a progressive disease characterized by extracellular deposition of misfolded proteins, leading to myocardial dysfunction and poor prognosis. Early and accurate diagnosis ...

Cleveland-based University Hospitals Harrington Heart & Vascular Institute has become the first site in Ohio to clinically administer Flyrcado for the detection of coronary artery disease and arterial ...

RUHX, the official charity of the Royal United Hospitals (RUH) Bath, has launched a £4 million appeal to fund a new PET-CT ...